Immunitas Therapeutics is developing targeted therapeutics using knowledge of human immunology to treat various cancers. Using expertise in single-cell genomics with customized machine learning, Immunitas is elucidating immune cells populations that are key actors in immuno-oncology. Immunitas then complements this insight with in-house therapeutic discovery using antibody display and immunization. Their lead program, IMT-009, is a monoclonal antibody that is currently in clinical trials for solid tumor and hematological malignancies.

Immunitas Therapeutics

Founded: 2019
Location: Waltham, MA
Employee range: 11 - 50
Clinical stage: Clin1/Clin2a
Therapy area: Multiple cancers
Drug types: ONC
Lead product: IMT-009
Funding: $58M B Aug 2021; $39M Nov 2019

Drug notes:

About:

Jobs: